Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 189

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

The NF1 gene revisited - from bench to bedside

Open access
Yap, Yoon-Sim, McPherson, John R., Ong, Choon-Kiat, Rozen, Steven G., Teh, Bin-Tean, Lee, Ann S. G., Callen, David F. · 2014 · Oncotarget

Abstract

// Yoon-Sim Yap 1,2 , John R. McPherson 3 , Choon-Kiat Ong 4,5 , Steven G. Rozen 3 , Bin-Tean Teh 4,5,6 , Ann S. G. Lee 7,8,9 and David F. Callen 10 1 Division of Medical Oncology, National Cancer Centre Singapore, Singapore 2 Faculty of Health Sciences, School of Medicine, University of Adelaide, Australia 3 Centre for Computational Biology, Cancer and Stem Cell Biology Program, Duke-National University of Singapore Graduate Medical School, Singapore 4 Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, Singapore 5 Division of Cancer and Stem Cell Biology, Duke–National University of Singapore Graduate Medical School, Singapore 6 Cancer Science Institute of Singapore, National University of Singapore, Singapore 7 Laboratory of Molecular Oncology, Division of Medical Sciences, National Cancer Centre Singapore, Singapore 8 Office of Clinical & Academic Faculty Affairs, Duke-National University of Singapore Graduate Medical School, Singapore 9 Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 10 Cancer Therapeutics Laboratory, Centre for Personalised Cancer Medicine, University of Adelaide, Australia Correspondence: Yoon-Sim Yap, email: // Keywords : neurofibromatosis type 1, NF1, neurofibromin, cancer Received : May 15, 2014 Accepted : July 7, 2014 Published : July 9, 2014 Abstract Neurofibromatosis type 1 (NF1) is a relatively common tumour predisposition syndrome related to germline aberrations of NF1 , a tumour suppressor gene. The gene product neurofibromin is a negative regulator of the Ras cellular proliferation pathway, and also exerts tumour suppression via other mechanisms. Recent next-generation sequencing projects have revealed somatic NF1 aberrations in various sporadic tumours. NF1 plays a critical role in a wide range of tumours. NF1 alterations appear to be associated with resistance to therapy and adverse outcomes in several tumour types. Identification of a patient’s germline or somatic NF1 aberrations can be challenging, as NF1 is one of the largest human genes, with a myriad of possible mutations. Epigenetic factors may also contribute to inadequate levels of neurofibromin in cancer cells. Clinical trials of NF1 -based therapeutic approaches are currently limited. Preclinical studies on neurofibromin-deficient malignancies have mainly been on malignant peripheral nerve sheath tumour cell lines or xenografts derived from NF1 patients. However, the emerging recognition of the role of NF1 in sporadic cancers may lead to the development of NF1 -based treatments for other tumour types. Improved understanding of the implications of NF1 aberrations is critical for the development of novel therapeutic strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.2194

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 189

Metadata

Authors
Yap, Y.-S., McPherson, J. R., Ong, C.-K., Rozen, S. G., Teh, B.-T., Lee, A. S. G., & Callen, D. F.
Venue
Oncotarget
Published
2014-07-07
Volume
5
Issue
15
Pages
5873-5892
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1522859997
Cited by
189
References
19
FWCI
5.04
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.